Plinabulin + Docetaxel + Placebo (matching plinabulin placebo)
Phase 3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance
Trial Timeline
Jun 1, 2026 → Dec 1, 2029
NCT ID
NCT07361484About Plinabulin + Docetaxel + Placebo (matching plinabulin placebo)
Plinabulin + Docetaxel + Placebo (matching plinabulin placebo) is a phase 3 stage product being developed by BeyondSpring for Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07361484. Target conditions include Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07361484 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Cancer